Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Inhibikase Therapeutics, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- +5 vs. Q1 2021
- Shares held
- 3.79M
- +3.63M (+2,233.5%) vs. Q1 2021
- Total value
- $10.6M
- +$9.65M (+989.7%) vs. Q1 2021
- New holders
- 9
- 4 more added
- Sold out
- 4
- 0 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 105 | $239.2M |
| Q1 2026 | 104 | $193.4M |
| Q4 2025 | 74 | $218.2M |
| Q3 2025 | 54 | $89.0M |
| Q2 2025 | 48 | $106.3M |
| Q1 2025 | 47 | $112.7M |
| Q4 2024 | 31 | $162.7M |
| Q3 2024 | 11 | $1.12M |
| Q2 2024 | 12 | $1.02M |
| Q1 2024 | 12 | $443.8K |
| Q4 2023 | 11 | $298.9K |
| Q3 2023 | 13 | $597.6K |
| Q2 2023 | 14 | $2.69M |
| Q1 2023 | 17 | $2.91M |
| Q4 2022 | 19 | $719.4K |
| Q3 2022 | 24 | $2.78M |
| Q2 2022 | 22 | $2.49M |
| Q1 2022 | 24 | $6.33M |
| Q4 2021 | 26 | $6.85M |
| Q3 2021 | 21 | $7.78M |
| Q2 2021 | 14 | $10.6M |
| Q1 2021 | 9 | $975.0K |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Inhibikase Therapeutics, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ACT Capital Management, LLC | 875,000 | $2.45M | 1.26% | +875,000 | New |
| Kepos Capital LP | 700,000 | $1.96M | 0.15% | +700,000 | New |
| Vanguard Group Inc | 470,615 | $1.32M | 0.00% | +470,615 | New |
| FMR LLC | 433,300 | $1.21M | 0.00% | +333,300+333.3% | Added |
| Sabby Management, LLC | 421,200 | $1.18M | 0.26% | +421,200 | New |
| Murchinson Ltd. | 320,947 | $899.0K | 0.33% | +320,947 | New |
| Antara Capital LP | 250,000 | $700.0K | 0.13% | +250,000 | New |
| Altium Capital Management LP | 109,749 | $307.0K | 0.07% | +109,749 | New |
| Zeke Capital Advisors, LLC | 93,800 | $263.0K | 0.02% | +75,000+398.9% | Added |
| Warberg Asset Management LLC | 90,000 | $252.0K | 0.08% | +90,000 | New |
| HRT Financial LP | 15,000 | $42.0K | 0.00% | +3,386+29.2% | Added |
| BlackRock Inc. | 13,571 | $38.0K | 0.00% | +13,000+2,276.7% | Added |
| Rockefeller Capital Management L.P. | 1,500 | $4.00K | 0.00% | +1,500 | New |
| Wells Fargo & Company | 12 | $0 | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −17,857−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −11,224−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −543−100.0% | Sold out |